{
    "clinical_study": {
        "@rank": "80477", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter observational study will evaluate the efficacy and safety of first-line\n      Avastin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy in patients\n      with metastatic colorectal cancer. Patients will be followed for up to 3.5 years."
        }, 
        "brief_title": "An Observational Study of Avastin (Bevacizumab) With First-Line Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients with histologically confirmed metastatic colorectal cancer who will receive\n             Avastin in combination with first-line fluoropyrimidine-based chemotherapy\n\n        Exclusion Criteria:\n\n          -  Patients not qualified for Avastin treatment according to the local label"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with metastatic colorectal cancer receiving Avastin in combination with\n        first-line fluoropyrimidine-based chemotherapy"
            }
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712347", 
            "org_study_id": "ML28233"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chai Yi", 
                        "country": "Taiwan", 
                        "zip": "613"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan", 
                        "zip": "807"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan", 
                        "zip": "00833"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan", 
                        "zip": "407"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan", 
                        "zip": "704"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "00112"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "114"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taoyuan", 
                        "country": "Taiwan", 
                        "zip": "333"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_groups": "1", 
        "official_title": "AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28233 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Food and Drugs Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival from the time of starting first-line therapy", 
            "safety_issue": "No", 
            "time_frame": "approximately 3.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival from the time of starting first-line therapy; tumor assessments according to RECIST v.1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Overall response rate (ORR), tumor assessments according to RECIST v.1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Liver resection rate in patients with liver metastasis only after the combination treatment with Avastin and any first-line fluoropyrimidine-based chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}